|Bid||0.00 x 1800|
|Ask||0.00 x 900|
|Day's Range||10.43 - 11.27|
|52 Week Range||5.50 - 15.00|
|Beta (5Y Monthly)||1.38|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 18, 2021 - Feb 22, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.33|
Alan Auerbach, CEO and President of Puma Biotechnology, will present a company update at the B. Riley Oncology Investor Conference on Jan. 21.
Puma Biotechnology presented interim results from its biliary tract cancers cohort of the Phase II SUMMIT "basket" trial at ASCO GI 2021,
Alan Auerbach will present an overview of Puma Biotechnology at the J.P. Morgan Healthcare Conference on Jan. 14 at 10:50 a.m. EST.